Precigen (PGEN) Stock Analysis: AI Score & Alternative Data
PGEN alt-data: job postings climbing, web traffic lagging
Is Precigen a buy right now? The alternative data says hold. This PGEN stock analysis is built on the 25+ alternative data signals AltIndex tracks on Precigen every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 59/100: a Hold. The stock trades at $7.20 with a $3B market cap.
The bullish side of the 90-day ledger: job postings up 33.3% to 12 open roles. The drag: web traffic down 20.8% to 7K monthly visits. That tension is what keeps the score mid-range.
PGEN’s broader alt-data profile also covers headcount (154 employees, according to LinkedIn), quarterly revenue ($50M), business outlook (62% of employees positive), and X followers (954). Every signal links to its own page with full history, the PGEN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on PGEN is just below.
Precigen AI Stock Analysis
Precigen is a biotechnology company that focuses on the development of gene and cell therapies. The company is known for its cutting-edge technology and research in synthetic biology and therapeutic development, striving to revolutionize healthcare through innovative scientific approaches.
Analysis generated October 1, 2026.
Recent Precigen Stock Alerts
|
Precigen | October 5 Price is down by -6.1% in the last 24h. |
|
Precigen | September 30 Price is up by 6.2% in the last 24h. |
|
Precigen | September 25 Price is up by 6.4% in the last 24h. |
|
Precigen | September 23 Price is down by -6.3% in the last 24h. |
Precigen Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 7K | 20.8% | |
| Job Posts | 12 | 33.3% | |
| LinkedIn Employees | 154 | 2.7% | |
| Wikipedia Views | 4 | 60.0% | |
| Employee Recommend | 64 | 0% | |
| Business Outlook | 62 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 5 | 150.0% | |
| Stocktwits Mentions | 18 | 30.8% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 9K | 2.0% | |
| X Followers | 954 | 0.6% | |
| Youtube Subscribers | 100 | 5.3% |
About Precigen (PGEN)
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
| Price | $7.20 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $3B |
| Year Range | $3 – $9 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Precigen News
View more → |
Precigen Receives FDA Platform Technology Designation for AdenoVerse PlatformSeptember 21 - PRNewswire |
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOSJune 20 - Yahoo Entertainment |
|
 |
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 YearsMay 30 - PRNewswire |
 |
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United StatesMay 27 - PRNewswire |
|
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26 - PRNewswire |
See Precigen’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for PGEN, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEPrecigen Earnings & Financial Performance
View all earnings →Precigen Insider Trading Activity
View all →| KINDLER JEFFREY B filed to sell 17,100 shares at $0.0. Aug 26 '26 |
| Tennant Phil filed to sell 141,992 shares at $0.0. Aug 25 '26 |
| Shah Rutul R filed to sell 468,865 shares at $0.0. Aug 25 '26 |
| AGEE NANCY H filed to sell 309,187 shares at $0.0. Aug 21 '26 |
| Shah Rutul R filed to sell 465,012 shares at $0.0. Aug 21 '26 |
Precigen Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Precigen
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Nurix TherapeuticsNRIX |
$24.95 5.4% | $3B | 54 |
 |
AtaiBeckleyATAI |
$7.35 0.8% | $3B | 65 |
 |
Soleno TherapeuticsSLNO |
$53.01 0.0% | $3B | 54 |
 |
Dyne TherapeuticsDYN |
$15.29 1.7% | $3B | 48 |
 |
Arcus BiosciencesRCUS |
$22.82 1.3% | $3B | 30 |
Explore Precigen Data
Frequently Asked Questions: Precigen (PGEN)
Precigen has an AltIndex AI Score of 59/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
59/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Precigen (PGEN) stock is $7.20 with a market cap of $3B.
As of today, Precigen’s PE (Price to Earnings) ratio is —.
View the latest Precigen insider transactions to see recent buying and selling activity by company executives and directors.
Check the Precigen congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The PGEN stock price chart above shows Precigen’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Precigen technical analysis for RSI, moving averages, and more.
See the stocks similar to Precigen section on this page for companies in the same industry ranked by market cap and AI Score.
